Outrage as men are to be stripped of their right to a prostate cancer test with Lord Cameron describing it as a ‘backwards step’
The article reports criticism of plans that could limit men’s access to prostate cancer testing, with Lord Cameron calling the move a “backwards step”. The issue matters because earlier testing can help identify prostate cancer sooner, although screening policy must also balance potential benefits against false positives and unnecessary treatment.
The supplied text does not include the article’s substantive reporting or the proposed policy details, so its precise scope, timing and evidence cannot be confirmed. The headline frames the change as removing a right to a test, but it is unclear whether this refers to routine screening, eligibility rules or access through a GP.
- Plans may restrict access to prostate cancer testing.
- Lord Cameron calls the reported change a backwards step.
- The provided text lacks the policy’s key details.
New here? Start with this
Prostate cancer is one of the most common cancers affecting men in the UK. It develops in the prostate, a small gland below the bladder, and often causes no symptoms at first.
Testing may include a PSA blood test, which measures a substance made by the prostate. A high result can be caused by cancer but also by non-cancerous conditions, so it does not provide a definite diagnosis on its own.
In the UK, there is no national routine screening programme for prostate cancer. Men can discuss PSA testing with their GP, particularly if they have symptoms, a family history of the disease or are at higher risk because of their age or ethnicity.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Opponents of tighter limits argue that men should be able to discuss and obtain appropriate prostate cancer testing, particularly where age, family history, ethnicity or symptoms put them at elevated risk. They contend that reducing access could delay diagnosis, deepen existing inequalities in outcomes and undermine informed choice; safeguards against unnecessary treatment need not mean denying a potentially valuable test to people who want it after proper advice.
The case against
Supporters of a more selective approach argue that population screening and testing policies must be guided by evidence, not simply by the intuitive appeal of earlier detection. PSA tests can produce false positives and find slow-growing cancers that would never cause harm, exposing men to anxiety, invasive follow-up and treatment side effects; clearer eligibility criteria and shared decision-making may therefore protect patients while directing resources towards those most likely to benefit.